Wednesday , March 29 2017
Home / 2015 / March

Monthly Archives: March 2015

Study Finds New Expensive Hepatitis C Drugs Are Only Cost-Effective for Certain Patients

A study, led by Boston Medical Center (BMC) researchers, assessed the cost-effectiveness of expensive new hepatitis C drugs and found that while they are highly effective, they are cost-effective and provide the greatest value in a specific groups of patients with hepatitis C. Findings from the study, led by Benjamin …

Read More »

Merck Teams Up with Syndax to Test Cancer Combination Regimen

Merck has teamed up with privately-held Syndax Pharmaceuticals to test combining Syndax’s investigational epigenetic therapy, entinostat, with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in cancer patients. The companies announced that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of this novel combination regimen in patients …

Read More »

NIH Names Working Group to Steer President Obama’s Precision Medicine Initiative

The National Institutes of Health (NIH) recently announced that a panel of experts will steer President Obama’s $215 million Precision Medicine Initiative. Obama’s vision includes a national research cohort of one million or more participants who will volunteer to share their biological, environmental, lifestyle and behavioral information, as well as …

Read More »

Fujifilm to Acquire Stem Cell Pioneer Cellular Dynamics for $307 Million

Japan’s Fujifilm said that it will pay more than $300 million for Wisconsin-based stem cell developer Cellular Dynamics International (CDI) to strengthen its presence in the regenerative field. The companies announced that they have entered into a definitive agreement, under which Fujifilm will acquire CDI. Fujifilm aims to acquire all …

Read More »

Merck Serono and Intrexon Strike CAR-T Therapy Collaboration

Merck Serono is partnering with Intrexon Corporation to develop Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. The companies announced today that they have entered an exclusive strategic collaboration and license agreement for CAR-T cancer drugs, advancing Merck Serono’s comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system’s …

Read More »

UnitedHealth to Acquire Pharmacy Benefit Manager Catamaran for $12.8 Billion

Today, health insurer UnitedHealth Group Inc. agreed to acquire pharmacy benefit manager (PBM) Catamaran Corp. for about $12.8 billion. Catamaran, the fourth-largest PBM in the US by volume of prescriptions processed, will be merged into OptumRx, UnitedHealth Group’s free-standing pharmacy care services business. UnitedHealth will pay $61.50 per share in …

Read More »

Teva Strengthens its CNS Portfolio with its $3.2 Billion Acquisition of Auspex

Today, Teva Pharmaceutical Industries Ltd. announced that it has agreed to acquire central nervous system (CNS) drug developer Auspex Pharmaceuticals, Inc. for about $3.2 billion. The companies said that they have entered into a definitive merger agreement, under which Teva will commence a tender offer for all of the outstanding …

Read More »

Novartis Enters $750 Million Immuno-Oncology Collaboration with Aduro Biotech

Swiss drugmaker Novartis is increasing its efforts in immuno-oncology, entering a $750 million research, development and commercialization agreement with Aduro Biotech, Inc. The companies announced a collaboration for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the Stimulator of …

Read More »